GemVax & KAEL Co (XKRX:082270) EBIT : ₩-51,393 Mil (TTM As of Sep. 2024)

View and export this data going back to 2005. Start your Free Trial

What is GemVax & KAEL Co EBIT?

GemVax & KAEL Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ₩-7,174 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ₩-51,393 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. GemVax & KAEL Co's annualized ROC % for the quarter that ended in Sep. 2024 was -28.27%. GemVax & KAEL Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -78.87%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. GemVax & KAEL Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -3.57%.

GemVax & KAEL Co EBIT Historical Data

The historical data trend for GemVax & KAEL Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GemVax & KAEL Co EBIT Chart

GemVax & KAEL Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-90,032.53

2,864.69

12,462.85

-19,158.44

-26,884.65

GemVax & KAEL Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															-7,322.34	-12,873.67	-34,272.65	2,927.40	-7,174.01

Competitive Comparison of GemVax & KAEL Co's EBIT

For the Semiconductor Equipment & Materials subindustry, GemVax & KAEL Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GemVax & KAEL Co's EV-to-EBIT Distribution in the Semiconductors Industry

For the Semiconductors industry and Technology sector, GemVax & KAEL Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where GemVax & KAEL Co's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

GemVax & KAEL Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-51,393 Mil.

GemVax & KAEL Co (XKRX:082270) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

GemVax & KAEL Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-35462.488 * ( 1 - -0.04% )	/	( (124239.59	+	126707.413)	/ 2 )
=	-35476.6729952	/	125473.5015
=	-28.27 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	138762.873	-	11988.819	-	( 18606.487	-	max(0, 30836.118	-	33370.582	+	18606.487	))
=	124239.59

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	144231.912	-	12327.118	-	( 20524.577	-	max(0, 31700.108	-	36897.489	+	20524.577	))
=	126707.413

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

GemVax & KAEL Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-28696.032	/	( ( (36561.828 + max(-4611.35, 0))	+	(36208.622 + max(-3834.253, 0)) )	/	2 )
=	-28696.032	/	( ( 36561.828	+	36208.622 )	/	2 )
=	-28696.032	/	36385.225
=	-78.87 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3656.412	+	8443.889	+	288.839)	-	(11988.819	+	0	+	5011.671)
=	-4611.35

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4473.651	+	9333.891	+	251.141)	-	(12327.118	+	0	+	5565.818)
=	-3834.253

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

GemVax & KAEL Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	-51392.922	/	1439629.212
	=	-3.57 %

GemVax & KAEL Co EBIT Related Terms

Thank you for viewing the detailed overview of GemVax & KAEL Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

GemVax & KAEL Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Technology » Semiconductors » GemVax & KAEL Co Ltd (XKRX:082270) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

894, Tamnip-Dong, Yuseong-Gu, Daejeon, KOR, 305-510

Website

http://www.kael.co.kr

GemVax & KAEL Co Ltd is primarily engaged in manufacturing and commercializing of coating resin and filters for semiconductors and panel display production. It offers chemical air filter, scrubber resin, and devices for preventing environmental contamination and eliminating harmful gas, for semiconductor and display industry. Its other business operations include research and development of anti-cancer immunotherapeutic and peptide drugs. The company organizes its business operations into three distinct segments: Environmental Pollution Control Business, IT Business, Bio-business. The company's product portfolio consists fundamental products, semiconductor, and display, equipment and system, fire evacuation mask 5aver.

GemVax & KAEL Co Headlines

No Headlines